|
|
|
|
Vol. 12, Issue 8, 2352-2363, August 2001
Department of Cell Biology, Neurobiology, and Anatomy, University
of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0521
The AP-1 transcription factor is activated by oncogenic signal
transduction cascades and its function is critical for both mitogenesis
and carcinogenesis. To define the role of AP-1 in the context of a
human fibrosarcoma cell line, HT1080, we expressed a dominant negative
c-jun mutant fused to the green fluorescent protein in
an ecdysone-inducible system. We demonstrated that high levels of this
mutant, GFP-TAM67, inhibit AP-1 activity and arrest cells predominately
in the G1 phase of the cell cycle. This arrest is reversible and occurs
only above a threshold concentration; low to moderate levels of
GFP-TAM67 are insufficient for growth arrest. Contrary to expectations
based on the literature, GFP-TAM67 does not inhibit expression of
cyclin D1, cyclin E, or their respective cyclin-dependent kinases.
However, pRB is hypophosphorylated in GFP-TAM67-arrested cells and the
activity of both the cyclin D1:cdk and the cyclin E:cdk complexes are
impaired. Both of these complexes show an increased association with
p21CIP1/WAF1, concomitantly with induction of the p21 mRNA
by GFP-TAM67. These results suggest a novel function of AP-1 in the
activation of the G1 cyclin:cdk complexes in human tumor cells by
regulating the expression of the p21CIP1/WAF1 gene.
This article has been cited by other articles:
![]() |
I-C. Wang, Y.-J. Chen, D. E. Hughes, T. Ackerson, M. L. Major, V. V. Kalinichenko, R. H. Costa, P. Raychaudhuri, A. L. Tyner, and L. F. Lau FoxM1 Regulates Transcription of JNK1 to Promote the G1/S Transition and Tumor Cell Invasiveness J. Biol. Chem., July 25, 2008; 283(30): 20770 - 20778. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Whibley, K. L. McPhail, R. A. Keyzers, M. F. Maritz, V. D. Leaner, M. J. Birrer, M. T. Davies-Coleman, and D. T. Hendricks Reactive oxygen species mediated apoptosis of esophageal cancer cells induced by marine triprenyl toluquinones and toluhydroquinones Mol. Cancer Ther., September 1, 2007; 6(9): 2535 - 2543. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Andersen, J. Mejlvang, S. Mahmood, I. Gromova, P. Gromov, E. Lukanidin, M. Kriajevska, J. K. Mellon, and E. Tulchinsky Immediate and Delayed Effects of E-Cadherin Inhibition on Gene Regulation and Cell Motility in Human Epidermoid Carcinoma Cells Mol. Cell. Biol., October 15, 2005; 25(20): 9138 - 9150. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yamaguchi, A. Lantowski, A. J. Dannenberg, and K. Subbaramaiah Histone Deacetylase Inhibitors Suppress the Induction of c-Jun and Its Target Genes Including COX-2 J. Biol. Chem., September 23, 2005; 280(38): 32569 - 32577. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. DeNardo, H.-T. Kim, S. Hilsenbeck, V. Cuba, A. Tsimelzon, and P. H. Brown Global Gene Expression Analysis of Estrogen Receptor Transcription Factor Cross Talk in Breast Cancer: Identification of Estrogen-Induced/Activator Protein-1-Dependent Genes Mol. Endocrinol., February 1, 2005; 19(2): 362 - 378. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. MacLaren, E. J. Black, W. Clark, and D. A. F. Gillespie c-Jun-Deficient Cells Undergo Premature Senescence as a Result of Spontaneous DNA Damage Accumulation Mol. Cell. Biol., October 15, 2004; 24(20): 9006 - 9018. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kielosto, P. Nummela, R. Katainen, V. Leaner, M. J. Birrer, and E. Holtta Reversible Regulation of the Transformed Phenotype of Ornithine Decarboxylase- and Ras-Overexpressing Cells by Dominant-Negative Mutants of c-Jun Cancer Res., June 1, 2004; 64(11): 3772 - 3779. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Cooper, J. MacGowan, J. Ranger-Moore, M. R. Young, N. H. Colburn, and G. T. Bowden Expression of Dominant Negative c-jun Inhibits Ultraviolet B-Induced Squamous Cell Carcinoma Number and Size in an SKH-1 Hairless Mouse Model Mol. Cancer Res., September 1, 2003; 1(11): 848 - 854. [Abstract] [Full Text] [PDF] |
||||